tipelukast

{{Chembox

| ImageFile = Tipelukast.svg

| IUPACName = 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenyl)sulfanylpropoxy]-2-propylphenoxy]butanoic acid

| OtherNames = KCA 757; MN-001

|Section1={{Chembox Identifiers

| CASNo = 125961-82-2

| ChEBI = 177735

| ChEMBL = 2104988

| DrugBank = DB12435

| KEGG = D06659

| PubChem = 9893228

| UNII = 08379P260O

| StdInChI=1S/C29H38O7S/c1-5-9-23-25(14-12-22(20(4)31)29(23)36-16-7-11-27(32)33)35-17-8-18-37-26-15-13-21(19(3)30)28(34)24(26)10-6-2/h12-15,34H,5-11,16-18H2,1-4H3,(H,32,33)

| StdInChIKey = KPWYNAGOBXLMSE-UHFFFAOYSA-N

| SMILES = CCCC1=C(C=CC(=C1OCCCC(=O)O)C(=O)C)OCCCSC2=C(C(=C(C=C2)C(=O)C)O)CCC

}}

|Section2={{Chembox Properties

| C=29|H=38|O=7|S=1

}}

|Section8={{Chembox Related

}}

}}

Tipelukast (KCA 757 or MN-001) is a sulfidopeptide leukotriene receptor antagonist with suspected anti-inflammatory properties. It is developed by MediciniNova.{{Cite web |title=MN-001 - MediciNova, Inc. |url=https://medicinova.com/clinical-development/core/mn-001-nash/ |access-date=3 December 2023 |website=medicinova.com}}{{Cite journal |last=Rajasekaran |first=Mahadevan |last2=Locke |first2=Kenneth W. |last3=Parsons |first3=C. Lowell |date=August 2006 |title=MN-001, a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model |journal=BJU International |volume=98 |issue=2 |pages=430–434 |doi=10.1111/j.1464-410X.2006.06274.x |pmid=16879690 |s2cid=44269457}}{{Cite journal |last=Matsuda |first=Kazuko |last2=Iwaki |first2=Yuichi |date=December 2014 |title=MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression in an advanced NASH (nonalcoholic steatohepatitis) model: LB-28 |url=https://journals.lww.com/hep/citation/2014/12000/mn_001__tipelukast_,_a_novel,_orally_bioavailable.76.aspx |journal=Hepatology |volume=60 |issue=6 |pages=1283A |issn=0270-9139}}{{Cite book |last=Bascom |first=R. |title=A37. Ild Therapy I |last2=Hitz |first2=K. |last3=Dimmock |first3=A.E.F. |last4=Makhay |first4=M. |last5=Dojillo |first5=J. |last6=Matsuda |first6=K. |date=May 2020 |pages=A1493 |chapter=Description of Protocol to Evaluate MN-001'S (tipelukast) Efficacy, Safety and Tolerability in Subjects with Idiopathic Pulmonary Fibrosis |doi=10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A1493 |s2cid=225921518}}